Cytokine-armed vaccinia virus promotes cytotoxicity toward pancreatic carcinoma cells via activation of human intermediary CD56
immune modulation
immunogenic cell death
modified vaccinia virus
natural killer cells
proteome analysis
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
14 Oct 2024
14 Oct 2024
Historique:
revised:
20
08
2024
received:
09
01
2024
accepted:
18
09
2024
medline:
14
10
2024
pubmed:
14
10
2024
entrez:
14
10
2024
Statut:
aheadofprint
Résumé
Pancreatic ductal adenocarcinoma (PDAC) remains a particularly aggressive disease with few effective treatments. The PDAC tumor immune microenvironment (TIME) is known to be immune suppressive. Oncolytic viruses can increase tumor immunogenicity via immunogenic cell death (ICD). We focused on tumor-selective (vvDD) and cytokine-armed Western-reserve vaccinia viruses (vvDD-IL2 and vvDD-IL15) and infected carcinoma cell lines as well as patient-derived primary PDAC cells. In co-culture experiments, we investigated the cytotoxic response and the activation of human natural killer (NK). Infection and virus replication were assessed by measuring virus encoded YFP. We then analyzed intracellular signaling processes and oncolysis via in-depth proteomic analysis, immunoblotting and TUNEL assay. Following the co-culture of mock or virus infected carcinoma cell lines with allogenic PBMCs or NK cell lines, CD56
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : China Scholarship Council
ID : 201908080257
Organisme : Clinician Scientist - Berlin Institute of Health (BIH)
Organisme : Else Kröner Fresenius Stiftung (EKFS)
Informations de copyright
© 2024 The Author(s). International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Bear AS, Vonderheide RH, O'Hara MH. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell. 2020;38(6):788‐802. doi:10.1016/j.ccell.2020.08.004
Rech AJ, Balli D, Mantero A, et al. Tumor immunity and survival as a function of alternative neopeptides in human cancer. Cancer Immunol Res. 2018;6(3):276‐287. doi:10.1158/2326‐6066.CIR‐17‐0559
Balachandran VP, Beatty GL, Dougan SK. Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology. 2019;156(7):2056‐2072. doi:10.1053/j.gastro.2018.12.038
Grosser R, Cherkassky L, Chintala N, Adusumilli PS. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 2019;36(5):471‐482. doi:10.1016/j.ccell.2019.09.006
Hall M, Liu H, Malafa M, et al. Expansion of tumor‐infiltrating lymphocytes (TIL) from human pancreatic tumors. J Immunother Cancer. 2016;4:61. doi:10.1186/s40425‐016‐0164‐7
Soares KC, Rucki AA, Wu AA, et al. PD‐1/PD‐L1 blockade together with vaccine therapy facilitates effector T‐cell infiltration into pancreatic tumors. J Immunother. 2015;38(1):1‐11. doi:10.1097/CJI.0000000000000062
Winograd R, Byrne KT, Evans RA, et al. Induction of T‐cell immunity overcomes complete resistance to PD‐1 and CTLA‐4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res. 2015;3(4):399‐411. doi:10.1158/2326‐6066.CIR‐14‐0215
Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD‐1 blockade. Science. 2017;357(6349):409‐413. doi:10.1126/science.aan6733
O'Reilly EM, Oh DY, Dhani N, et al. Durvalumab with or without Tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5(10):1431‐1438. doi:10.1001/jamaoncol.2019.1588
Guo ZS, Lu B, Guo Z, et al. Vaccinia virus‐mediated cancer immunotherapy: cancer vaccines and oncolytics. J Immunother Cancer. 2019;7(1):6. doi:10.1186/s40425‐018‐0495‐7
Guo ZS, Naik A, O'Malley ME, et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI‐1 and SPI‐2. Cancer Res. 2005;65(21):9991‐9998. doi:10.1158/0008‐5472.CAN‐05‐1630
Heo J, Reid T, Ruo L, et al. Randomized dose‐finding clinical trial of oncolytic immunotherapeutic vaccinia JX‐594 in liver cancer. Nat Med. 2013;19(3):329‐336. doi:10.1038/nm.3089
Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780‐2788. doi:10.1200/JCO.2014.58.3377
McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumor‐selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001;61(24):8751‐8757.
Liu Z, Ravindranathan R, Li J, Kalinski P, Guo ZS, Bartlett DL. CXCL11‐armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy. Onco Targets Ther. 2016;5(3):e1091554. doi:10.1080/2162402X.2015.1091554
Liu Z, Ge Y, Wang H, et al. Modifying the cancer‐immune set point using vaccinia virus expressing re‐designed interleukin‐2. Nat Commun. 2018;9(1):4682. doi:10.1038/s41467‐018‐06954‐z
Kowalsky SJ, Liu Z, Feist M, et al. Superagonist IL‐15‐armed oncolytic virus elicits potent antitumor immunity and therapy that are enhanced with PD‐1 blockade. Mol Ther. 2018;26(10):2476‐2486. doi:10.1016/j.ymthe.2018.07.013
Waldmann TA. The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol Res. 2015;3(3):219‐227. doi:10.1158/2326‐6066.CIR‐15‐0009
Hernandez R, Poder J, LaPorte KM, Malek TR. Engineering IL‐2 for immunotherapy of autoimmunity and cancer. Nat Rev Immunol. 2022;22(10):614‐628. doi:10.1038/s41577‐022‐00680‐w
Malek TR, Yu A, Vincek V, Scibelli P, Kong L. CD4 regulatory T cells prevent lethal autoimmunity in IL‐2Rbeta‐deficient mice. Implications for the nonredundant function of IL‐2. Immunity. 2002;17(2):167‐178. doi:10.1016/s1074‐7613(02)00367‐9
Lee YH, Ishida Y, Rifa'i M, Shi Z, Isobe K, Suzuki H. Essential role of CD8+CD122+ regulatory T cells in the recovery from experimental autoimmune encephalomyelitis. J Immunol. 2008;180(2):825‐832. doi:10.4049/jimmunol.180.2.825
Cozar B, Greppi M, Carpentier S, Narni‐Mancinelli E, Chiossone L, Vivier E. Tumor‐infiltrating natural killer cells. Cancer Discov. 2021;11(1):34‐44. doi:10.1158/2159‐8290.CD‐20‐0655
Huntington ND, Cursons J, Rautela J. The cancer‐natural killer cell immunity cycle. Nat Rev Cancer. 2020;20(8):437‐454. doi:10.1038/s41568‐020‐0272‐z
Ljunggren HG, Karre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today. 1990;11(7):237‐244. doi:10.1016/0167‐5699(90)90097‐s
Westhaver LP, Nersesian S, Nelson A, et al. Mitochondrial damage‐associated molecular patterns trigger arginase‐dependent lymphocyte immunoregulation. Cell Rep. 2022;39(8):110847. doi:10.1016/j.celrep.2022.110847
Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17(2):97‐111. doi:10.1038/nri.2016.107
Nelson A, Gebremeskel S, Lichty BD, Johnston B. Natural killer T cell immunotherapy combined with IL‐15‐expressing oncolytic virotherapy and PD‐1 blockade mediates pancreatic tumor regression. J Immunother Cancer. 2022;10(3). doi:10.1136/jitc‐2021‐003923
Parato KA, Breitbach CJ, Le Boeuf F, et al. The oncolytic poxvirus JX‐594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther. 2012;20(4):749‐758. doi:10.1038/mt.2011.276
Santos CR, Vega FM, Blanco S, Barcia R, Lazo PA. The vaccinia virus B1R kinase induces p53 downregulation by an Mdm2‐dependent mechanism. Virology. 2004;328(2):254‐265. doi:10.1016/j.virol.2004.08.013
Vayrynen SA, Zhang J, Yuan C, et al. Composition, spatial characteristics, and prognostic significance of myeloid cell infiltration in pancreatic cancer. Clin Cancer Res. 2021;27(4):1069‐1081. doi:10.1158/1078‐0432.CCR‐20‐3141
Yamamoto K, Venida A, Yano J, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC‐I. Nature. 2020;581(7806):100‐105. doi:10.1038/s41586‐020‐2229‐5
Okumura G, Iguchi‐Manaka A, Murata R, Yamashita‐Kanemaru Y, Shibuya A, Shibuya K. Tumor‐derived soluble CD155 inhibits DNAM‐1‐mediated antitumor activity of natural killer cells. J Exp Med. 2020;217(4):1. doi:10.1084/jem.20191290
Raafat N, Sadowski‐Cron C, Mengus C, Heberer M, Spagnoli GC, Zajac P. Preventing vaccinia virus class‐I epitopes presentation by HSV‐ICP47 enhances the immunogenicity of a TAP‐independent cancer vaccine epitope. Int J Cancer. 2012;131(5):E659‐E669. doi:10.1002/ijc.27362
Jarahian M, Fiedler M, Cohnen A, et al. Modulation of NKp30‐ and NKp46‐mediated natural killer cell responses by poxviral hemagglutinin. PLoS Pathog. 2011;7(8):e1002195. doi:10.1371/journal.ppat.1002195
Davis M, Conlon K, Bohac GC, et al. Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas. J Immunother. 2012;35(8):629‐640. doi:10.1097/CJI.0b013e31826c8a4f
Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK‐cell cytokine and chemokine production by target cell recognition. Blood. 2010;115(11):2167‐2176. doi:10.1182/blood‐2009‐08‐238469
Lim SA, Kim J, Jeon S, et al. Defective localization with impaired tumor cytotoxicity contributes to the immune escape of NK cells in pancreatic cancer patients. Front Immunol. 2019;10:496. doi:10.3389/fimmu.2019.00496
Pandha H, Rigg A, John J, Lemoine N. Loss of expression of antigen‐presenting molecules in human pancreatic cancer and pancreatic cancer cell lines. Clin Exp Immunol. 2007;148(1):127‐135. doi:10.1111/j.1365‐2249.2006.03289.x
Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress‐inducible MICA. Science. 1999;285(5428):727‐729. doi:10.1126/science.285.5428.727
Bottino C, Castriconi R, Pende D, et al. Identification of PVR (CD155) and Nectin‐2 (CD112) as cell surface ligands for the human DNAM‐1 (CD226) activating molecule. J Exp Med. 2003;198(4):557‐567. doi:10.1084/jem.20030788
Fiore PF, Di Matteo S, Tumino N, et al. Interleukin‐15 and cancer: some solved and many unsolved questions. J Immunother Cancer. 2020;8(2). doi:10.1136/jitc‐2020‐001428
Chalikonda S, Kivlen MH, O'Malley ME, et al. Oncolytic virotherapy for ovarian carcinomatosis using a replication‐selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther. 2008;15(2):115‐125. doi:10.1038/sj.cgt.7701110
Zeh HJ, Downs‐Canner S, McCart JA, et al. First‐in‐man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity. Mol Ther. 2015;23(1):202‐214. doi:10.1038/mt.2014.194
Bartlett DL, Liu Z, Sathaiah M, et al. Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer. 2013;12(1):103. doi:10.1186/1476‐4598‐12‐103
Dai MH, Liu SL, Chen NG, et al. Oncolytic vaccinia virus in combination with radiation shows synergistic antitumor efficacy in pancreatic cancer. Cancer Lett. 2014;344(2):282‐290. doi:10.1016/j.canlet.2013.11.007
Yu YA, Galanis C, Woo Y, et al. Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV‐1h68. Mol Cancer Ther. 2009;8(1):141‐151. doi:10.1158/1535‐7163.MCT‐08‐0533
Amand M, Iserentant G, Poli A, et al. Human CD56(dim)CD16(dim) cells As an individualized natural killer cell subset. Front Immunol. 2017;8:699. doi:10.3389/fimmu.2017.00699
Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126(4):458‐465. doi:10.1111/j.1365‐2567.2008.03027.x
John LB, Howland LJ, Flynn JK, et al. Oncolytic virus and anti‐4‐1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res. 2012;72(7):1651‐1660. doi:10.1158/0008‐5472.CAN‐11‐2788
Prager I, Liesche C, van Ooijen H, et al. NK cells switch from granzyme B to death receptor‐mediated cytotoxicity during serial killing. J Exp Med. 2019;216(9):2113‐2127. doi:10.1084/jem.20181454